Bone Marrow Transplant Market Size, Share, Opportunities, And Trends By Transplant Type (Autologous Bone Marrow Transplant, Allogeneic Bone marrow Transplant, Others), By Disease Indication (Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndrome, Myeloproliferative Disorders, Aplastic Anemia, Solid Tumors, Sickle cell Anemia, Thalassemia, Others), By End-User (Hospitals, Multispeciality Clinics, Ambulatory Surgical Centers), And By Geography - Forecasts From 2024 To 2029

The Bone marrow transplant market is anticipated to experience growth in the upcoming period.

A bone marrow transplant is a medical procedure that replaces damaged or diseased bone marrow with healthy cells, either from the patient's body or a donor. The bone marrow, a spongy tissue in bones, is crucial for blood cell production, including red blood cells, white blood cells, and platelets. A bone marrow transplant, also known as a hematopoietic stem cell transplant, involves harvesting immature stem cells from the patient or a compatible donor. These stem cells are infused into the patient's bloodstream, allowing them to migrate to the bone marrow and produce new, healthy blood cells. This procedure can be used to treat cancers like leukemia, myeloma, and lymphoma, as well as non-cancerous disorders like aplastic anemia, immune system disorders, and genetic diseases affecting the bone marrow.

Improvement in gene therapy and bone marrow transplant

Bone marrow transplant is the only known cure for Sickle Cell Disease (SCD). Sickle Cell Disease (SCD), a genetic disorder causing severe pain, organ damage, anemia, and life-threatening complications, has been the subject of ongoing research and treatment. A recent breakthrough in bone marrow transplant technology, the FDA's approval of two gene therapies, Casgevy and Lyfgenia, could significantly change the treatment landscape for SCD. These therapies manipulate genes and reintroduce modified stem cells into patients, offering long-term pain relief and preventing complications. The University of Michigan Health is working on logistics to offer these therapies to patients aged 12 to 25. Also, A preclinical study published in Science demonstrates that mRNA technology could simplify and provide safer treatment of genetic blood diseases. The study explores how mRNA could replace toxic chemotherapy and radiation procedures, and how researchers can correct gene mutations at their source and genetically alter blood stem cells or bone marrow cells in vivo using the same platform.

Advancements in graft-versus-host prophylaxis, and HLA genotyping technology

Haploidentical donors offer a larger pool of potential donors for bone marrow transplants, making them more accessible to a wider range of patients. Identifying a haploidentical donor is often faster than finding a fully matched unrelated donor, especially for patients from ethnically diverse backgrounds. Family involvement in haploidentical transplantation fosters support and care during the transplantation process, leading to increased compliance with post-transplant care. However, the higher risk of graft-versus-host disease (GVHD) is a challenge, which can be mitigated through techniques like T cell depletion before transplantation or in vivo T cell manipulation after transplantation. Post-transplant immune recovery strategies, such as cytokines and growth factors, are often employed to help the recipient rebuild a functional immune system. Advancements in transplantation techniques, such as post-transplant cyclophosphamide, have improved the outcomes of haploidentical transplantation. Historically, bone marrow transplants were performed on human leukocyte antigen (HLA)-matched or unrelated donors due to the risk of graft-versus-host-disease. Advances in HLA genotyping and clinical management have led to the successful use of mismatched donors, such as haploidentical-related transplants and permissively HLA mismatched transplants. These advances have expanded transplant access for non-Caucasian ethnic groups, reducing the risk of graft failure or GVHD.

Innovation in Bone Marrow Transplantation Technology

Technological advancements in bone marrow transplantation have improved safety, efficacy, and accessibility. HLA typing technologies have enhanced matching accuracy, reducing complications and graft-versus-host disease (GVHD). Reduced-intensity conditioning regimens make transplantation more accessible for older patients and those with underlying health conditions. Cord blood transplants have expanded the donor pool, and innovations in graft engineering have improved transplant outcomes. Cellular therapies and gene editing technologies are promising for treating certain hematological malignancies. Targeted therapies for GVHD are being developed to modulate the immune response more precisely. Telemedicine and virtual consultations have improved pre- and post-transplant care. Regenerative medicine approaches are also being explored for reducing transplantation needs or improving post-transplant outcomes.

Various government schemes and financial assistance programs are offered

India faces a significant burden of Thalassemia and Aplastic anemia, with over 10,000 children born annually and 9400 diagnosed annually. The government is implementing the Thalassemia Bal Sewa Yojana, providing financial assistance of up to Rs.10 lakh to eligible patients for bone marrow transplants in ten prominent hospitals across the country. Coal India Limited has implemented the program under the Ministry of Health & Family Welfare, empaneled in reputable hospitals such as AIIMS, CMC Vellore, and Tata Medical Centre. Additionally, The Ayushman Bharat Scheme, launched by the National Health Authority (NHA), is now covering bone marrow transplants, a costly procedure, and other medical procedures in India. The scheme offers better health services to the poor and vulnerable, covering over 365 procedures and providing monetary assistance for secondary and tertiary care hospitalization. The National Health Authority has launched a public dashboard to share real-time information on the scheme, under the flagship Ayushman Bharat Digital Mission (ABDM).

Bone marrow transplant Market in Europe region is anticipated to grow steadily. 

Europe is expected to dominate the global market for bone marrow transplants due to its increasing geriatric population and innovative healthcare systems. Advancements in medical technology, stem cell research, and supportive care have made bone marrow transplants more widely accepted. The increasing incidence of hematological disorders, strong healthcare infrastructure, collaborations on medical research, increased awareness and donor recruitment, and international cooperation are also contributing factors to the market's steady growth. The growing demand for transplantation services is driven by the growing population, improved diagnostic capabilities, and the availability of advanced medical facilities and skilled professionals.

Market Key Developments

• In July 2023, Ossium Health, a bioengineering company, raised $52 million in a Series C funding round. The funding will be used to expand Ossium's proprietary bone marrow bank, accelerate clinical trials, and develop new products. The company aims to improve human health, vitality, and longevity through bioengineering. Traditionally, bone marrow transplants are limited due to the healthcare industry's reliance on living, volunteer donors. Ossium's proprietary recovery, processing, and cryopreservation methods increase the accessibility of treatment and can deliver them months faster than traditional options.
• In March 2023, Researchers at the University of Missouri School of Medicine developed a process to mark transplanted donor bone marrow cells, allowing immune cells to only attack cancerous cells and not healthy tissue. This discovery could provide a new lease for the treatment of blood cancers such as leukemia and lymphoma, which are frequently treated as a last option because of graft-versus-host disease (GVHD), a condition in which the recipient's healthy and malignant cells are attacked by immune cells from the donor transplant.
• In May 2022, The Indian Council of Medical Research (ICMR) plans to establish advanced research centers for bone marrow transplant (BMT) in government hospitals across India. The institute believes BMT is a high-end procedure for critically ill patients, and most centers are in the private sector, limiting access to treatment for the poor. The ICMR will support medical institutions in setting up state-of-the-art infrastructure for BMT, providing safe and affordable procedures in all six regions of India, and analyzing disease burden in specific regions.

Segmentation:

• By Transplant Type
  • Autologous Bone Marrow Transplant
  • Allogeneic Bone marrow Transplant
  • Others
• By Disease Indication
  • Leukemia
  • Lymphoma
  • Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Disorders
  • Aplastic Anemia
  • Solid Tumors
  • Sickle cell Anemia
  • Thalassemia
  • Others
• By End-User
  • Hospitals
  • Multispeciality Clinics
  • Ambulatory Surgical Centers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. BONEMARROW TRANSPLANT MARKET BY TRANSPLANT TYPE

5.1. Introduction

5.2. Autologous Bone Marrow Transplant

5.3. Allogeneic Bone Marrow Transplant

5.4. Others

6. BONEMARROW TRANSPLANT MARKET BY DISEASE INDICATION

6.1. Introduction

6.2. Leukemia

6.3. Lymphoma

6.4. Multiple Myeloma

6.5. Myelodysplastic Syndrome

6.6. Myeloproliferative Disorders

6.7. Aplastic Anemia

6.8. Solid Tumors

6.9. Sickle Cell Anemia

6.10. Thalassemia

6.11. Others

7. BONEMARROW TRANSPLANT MARKET BY END-USER

7.1. Introduction

7.2. Hospitals

7.3. Multispeciality Clinics

7.4. Ambulatory Surgical Centers

8. BONEMARROW TRANSPLANT MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. United States

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1. Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. United Kingdom

8.4.2. Germany

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. The Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. Japan

8.6.2. China

8.6.3. India

8.6.4. South Korea

8.6.5. Indonesia

8.6.6. Thailand

8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

10.1. Mayo Clinic

10.2. Fred Hutchinson Cancer Research Center

10.3. Memorial Sloan Kettering Cancer Center

10.4. Gleneagles Global Hospitals 

10.5. John Hopkins Medicine

10.6. Narayana Superspeciality Hospital

10.7. Royal Marsden Hospital

10.8. Charité – Universitätsmedizin Berlin

10.9. Apollo Hospitals

10.10. National University Hospital (NUH)

10.11. Asan Medical Center

Mayo Clinic

Fred Hutchinson Cancer Research Center

Memorial Sloan Kettering Cancer Center

Gleneagles Global Hospitals

John Hopkins Medicine

Narayana Superspeciality Hospital

Royal Marsden Hospital

Charité – Universitätsmedizin Berlin

Apollo Hospitals

National University Hospital (NUH)

Asan Medical Center